Microchip Biotechnologies Inc.
This article was originally published in Start Up
Even as next-generation sequencing technologies make their way to the market, improving the efficiency of sample prep at the front end of large-scale genome sequencing will continue to be a viable strategy for significantly driving down costs and in so doing, expand applications. That's the initial strategy of Microchip Biotechnologies, which is commercializing microfluidic technology originally developed in the lab of Richard Mathies at Berkeley.
You may also be interested in...
Even if most attempts to read DNA strands in real time appear stalled and the goal of true single-molecule sequencing has, with the notable exception of Helicos, for the most part given way (at least for the time being) in favor of cluster-based approaches with lower data densities, there's still plenty of opportunity for start-ups to advance the field of next-generation sequencing: with microfluidics, nanotechnology, and biochemistries to better enable direct DNA observation and analysis.
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.